Table 3.
Hazard ratio (HR) with 95% CI for secondary primary malignancies according to radiotherapy, PSA, and Gleason score in the cohort study, 1998–2012
| Total number of cases | SPM patients |
||
|---|---|---|---|
| Age-adjusted HR | Multivariate-adjusted HR | ||
| Radiation therapy | |||
| No | 27 | 1.00 | 1.00 |
| Yes | 12 | 0.36 (0.10–1.29) | 0.18 (0.03–1.21) |
| PSA fail | |||
| No | 30 | 1.00 | 1.00 |
| Yes | 11 | 1.38 (0.35–5.45) | 0.42 (0.06–3.07) |
| Gleason score | |||
| 6 | 15 | 1.00 | 1.00 |
| 7 | 19 | 1.14 (0.22–5.82) | 0.76 (0.06–9.40) |
| 8 | 7 | 1.44 (0.30–6.94) | 1.14 (0.14–9.36) |
| Extra prostatic extension | |||
| No | 27 | 1.00 | 1.00 |
| Yes | 14 | 0.86 (0.31–2.44) | 1.17 (0.12–11.64) |
| Surgical margin | |||
| No | 20 | 1.00 | 1.00 |
| Yes | 21 | 0.77 (0.26–2.30) | 0.41 (0.06–3.02) |
| Seminal vesicle invasion | |||
| No | 34 | 1.00 | 1.00 |
| Yes | 7 | 1.12 (0.32–3.95) | 4.51 (0.26–78.69) |
Adjusted model for age (y), radiation therapy (yes/no), PSA failure (yes/no), Gleason score (6, 7, and > 8), extra prostatic extension (yes/no), surgical margin (yes/no), and seminal vesicle invasion (yes/no).
CI, confidence interval; HR, hazard ratio; PSA, prostate-specific antigen; SPM, second primary malignancy.